IP Library Granted Patent US 7,459,287
Granted Patent B2
US 7,459,287 · App. 11/046,346 · Granted Dec 2, 2008

Method for determination and quantification of radiation or genotoxin exposure

Assignee: Dana Farber Cancer Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,287
App. No.
11/046,346
Granted
Dec 2, 2008
Kind
B2
Abstract

The present invention discloses methods for detecting exposure of a living subject to genotoxic agents, testing sensitivity to a genotoxic agent, and determining DNA damage caused by exposure to an agent, comprising detecting the presence of FANCD2-containing foci from a sample collected from said subject. The presence of concentrated foci is indicative of DNA damage, and the degree of foci formation is correlated with degree of exposure. Diagnostic reagents contain a ligand that binds to human FANCD2 associated with a detectable label. Kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. The invention further discloses methods for identifying agents which modulate the ability of FANCD2-containing foci to form. Among other things, such agents are potentially useful chemosensitizing agents or may confer protection against damage caused by genotoxic agents.

Claims (17)

1. A method of screening test agents which modulate formation of FANCD2-containing foci, said method comprising:

identifying an individual suspected of having been exposed to a genotoxic agent;

obtaining a biological sample from said individual;

contacting said biological sample with test compound; and

detecting the presence of FANCD2 in FANCD2-containing foci relative to a control sample, wherein a difference in the degree of foci formation relative to a control sample is indicative of an agent active in foci formation, wherein said biological sample is a cell expressing a polynucleotide comprising a DNA sequence encoding the human FACD2 protein of SEQ ID NO:1 fused in frame with a DNA sequence encoding a fluorescent protein.

2. The method of claim 1 , wherein said detecting comprises fluorescence microscopy.

3. The method of claim 1 , wherein said detecting comprises measuring fluorescence resonance energy transfer.

4. A method of screening test agents which modulate formation of FANCD2-containing foci, said method comprising:

identifying an individual suspected of having been exposed to a genotoxic agent;

obtaining a biological sample from said individual;

contacting said biological sample with test compound; and

detecting the presence of FANCD2 in FANCD2-containing foci relative to a control sample, wherein a difference in the degree of foci formation relative to a control sample is indicative of an agent active in foci formation, wherein said biological sample is a cell expressing a polynucleotide comprising a DNA sequence encoding a protein that binds with FANCD2 upon foci formation, fused in frame with a DNA sequence encoding a second fluorophore.

5. A method of screening test agents which modulate formation of FANCD2-containing foci, said method comprising:

identifying an individual suspected of having been exposed to a genotoxic agent;

obtaining a biological sample from said individual;

contacting said biological sample with test compound; and

detecting the presence of FANCD2 in FANCD2-containing foci relative to a control sample, wherein a difference in the degree of foci formation relative to a control sample is indicative of an agent active in foci formation, wherein said biological sample is a cell expressing a polynucleotide comprising a DNA sequence encoding the human FACD2 protein of SEQ ID NO:1 fused in frame with a DNA sequence encoding a fluorescent protein and a polynucleotide comprising a DNA sequence encoding a protein that binds with FANCD2 upon foci formation, fused in frame with a DNA sequence encoding a second fluorophore.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 2, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040798/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2005
From: D'ANDREA, ALAN
To: DANA FARBER CANCER INSTITUTE, INC.
Reel/Frame 016733/0732 →
Continuity (2)
Provisional Application 6054038000 · Jan 30, 2004
Related Publication 20050255502A1 · Nov 17, 2005